Investigational drug · Phase 2
roginolisib
Also called: IOA-244
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myelofibrosis (MF), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "roginolisib"
First trial start
2025
Feb 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "roginolisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelofibrosis (MF)
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Advanced Non Squamous NSCLC
- Uveal Melanoma
- Ocular Melanoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Myelofibrosis · Oncology · Hematology and blood cancers · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "roginolisib" as an intervention, largest first.
- A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal MelanomaActive, not recruiting
iOncturaIndustry
NCT06717126 · 85 participants (planned) · Start Feb 27, 2025 · Primary completion Dec 2027
Drug: roginolisib; Investigator choice of standard therapy · For: Uveal Melanoma; Ocular Melanoma
Sites: Bari, Italy; Naples, Italy; Padova, Italy · 16 sites in all
The Lymphoma Academic Research OrganisationAcademic, hospital or other
NCT07018752 · 80 participants (planned) · Start Aug 20, 2025 · Primary completion Apr 2028
Drug: roginolisib; golcadomide and 2 more · For: Peripheral T Cells Lymphoma (PTCL); Follicular Helper T-Cell Lymphoma
Sites: Angers, France; Caen, France; Clermont-Ferrand, France · 20 sites in all
Jennifer R. Brown, MD, PhDAcademic, hospital or other
NCT06644183 · 64 participants (planned) · Start Mar 19, 2025 · Primary completion Oct 1, 2028
Drug: Roginolisib; Venetoclax and 1 more · For: Leukemia; Relapsed Leukemia; Chronic Lymphocytic Leukemia and 2 more
Sites: Boston, Massachusetts
- A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsActive, not recruiting
iOncturaIndustry
NCT06879717 · 45 participants (planned) · Start Apr 22, 2025 · Primary completion Jan 2027
Drug: roginolisib; Dostarlimab and 1 more · For: Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLC
Sites: Antwerp, Belgium; Roeselare, Belgium; Meldola, Italy · 7 sites in all
iOncturaIndustry
NCT05027568 · 40 participants · Start Jun 28, 2021 · Primary completion Sep 7, 2021
Drug: IOA-289; Nab paclitaxel / gemcitabine · For: Healthy
Sites: Verona, Italy
- Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLNot yet recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07847957 · 40 participants (planned) · Start Jan 13, 2027 · Primary completion Apr 1, 2027
Drug: Roginolisib; Obinutuzumab and 1 more · For: Chronic Lymphocytic Leukemia (CLL); Refractory Chronic Lymphocytic Leukemia
Sites: Boston, Massachusetts · 2 sites in all
iOncturaIndustry
NCT06887803 · 26 participants (planned) · Start Nov 17, 2025 · Primary completion Mar 2028
Drug: Roginolisib · For: Myelofibrosis (MF)
Sites: Florence, Italy; Rozzano, Italy; Bologna, Italy · 12 sites in all
St Vincent's Hospital, SydneyAcademic, hospital or other
NCT07203391 · 8 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 1, 2027
Drug: roginolisib · For: Uveal Melanoma, Metastatic
Sites: Sydney, Australia; Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Author Correction: The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.
Di Giacomo AM, Simonelli M, Losurdo A, et al. · Nat Commun 2026
- PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12.
Vadas O, Tiede S, Chaouki M, et al. · Nat Commun 2026
- The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.
Di Giacomo AM, Simonelli M, Losurdo A, et al. · Nat Commun 2026
- Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.
Villarreal Hernandez J, Carbonero JOD, Paoli C, et al. · Onco Targets Ther 2026
- An interpretable consensus pipeline for candidate dopamine D2 receptor ligands.
Mtambo S, Kumalo HM, Ssemakalu CC · In Silico Pharmacol 2026
- Application of sample stabilization and mass cytometry in global oncology trials: lessons from regulatory T cell monitoring.
Lahn M, Di Conza G, Magee K, et al. · Bioanalysis 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.